Publication date: January 2027 Source: Fitoterapia, Volume 196 Author(s): Gideovania de Jesus Santos, Cleosmarkson Menezes do Couto, Daniel Alves de Souza, Jéssica Maria Dantas Araújo Aragão, Letícia de Souza Ramos, Renata Grespan, Enilton Aparecido Camargo
Appraising the gastroprotective effects of isoflavones in peptic ulcer disease models: A systematic review of in vivo studies. // Fitoterapia. – URL: https://www.sciencedirect.com/science/article/pii/S0367326X26004582?dgcid=rss_sd_all
Appraising the gastroprotective effects of isoflavones in peptic ulcer disease models: A systematic review of in vivo studies. Fitoterapia. https://www.sciencedirect.com/science/article/pii/S0367326X26004582?dgcid=rss_sd_all
“Appraising the gastroprotective effects of isoflavones in peptic ulcer disease models: A systematic review of in vivo studies.” Fitoterapia.
@article{article46073,
title = {Appraising the gastroprotective effects of isoflavones in peptic ulcer disease models: A systematic review of in vivo studies},
journal = {Fitoterapia},
url = {https://www.sciencedirect.com/science/article/pii/S0367326X26004582?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...